Eric J.G. Sijbrands
机构: Professor of vascular medicine, Erasmus University Medical Center
主页: linkscience.org
每年引用次数
引用次数
引用: 48,843
H-指数: 91
I10-指数 : 267
出版物: 503
Het karakteriseren van puntmutaties in het low-density lipoproteïne gen in Nederlandse patiënten met heterozygote familiaire hypercholesterolemie
L. Havekes , R. Frants , J. Kastelein , P. Lombardi
Cate, J.W. ten, Trombose, atherosclerose en ontsteking, 163-164 163
1995
Characterization of point mutations in the LDL receptor gene in Dutch patients with heterozygous familial hypercholesterolemia (FH)
P. Lombardi , E. Sijbrands , J.C. Defesche , J.J.P. Kastelein
Atherosclerosis 109 112
1994
CC1 COST-EFFECTIVENESS OF SCREENING AND TREATING CHILDREN WITH FAMILIAL HYPERCHOLESTEROLEMIA EARLY IN LIFE FROM A DUTCH HEALTHCARE PERSPECTIVE
Z. Ademi , R. Norman , J. Pang , B. Ference
Value in Health 22
2019
Use of flavanols in type 2 diabetes mellitus with microalbuminuria (FLAVA-TRIAL): A randomized controlled multicenter trial
K. Berk , M. Rashid , A. Verhoeven , M. Mulder
Clinical nutrition ESPEN 40 502
2020
Pro- and anti-inflammatory cytokine gene expression in subcutaneous and visceral fat in severe obesity.
B. Spoto , E. Di Betta , F. Mattace-Raso , E. Sijbrands
Nutrition Metabolism and Cardiovascular Diseases 24 ( 10) 1137 -1143
37
2014
The fat-mass and obesity-associated gene (FTO) predicts mortality in chronic kidney disease of various severity
B. Spoto , F. Mattace-Raso , E. Sijbrands , F. Mallamaci
Nephrology Dialysis Transplantation 27
22
2012
PO23-746 ISIS 301012, AN ANTISENSE INHIBITOR OF APO B, PRODUCES SIGNIFICANT ADDITIONAL REDUCTION OF LDL-C & APOB IN HYPERCHOLESTEROLEMIC SUBJECTS ON STATINS NOT MEETING TARGET
J.P. Kastelein , F. Akdim , M.D. Trip , E. Sijbrands
Atherosclerosis Supplements 8 ( 1) 198 -199
5
2007
The Association Of The Igg N-Glycome With The Course Of Kidney Function In Type 2 Diabetes Mellitus
C. Meulen , S. Singh , A. Lieverse , O. Gornik
Atherosclerosis 287
2019
Igg N-Glycan Patterns Are Associated With Ischemic Heart Disease In Type 2 Diabetes
R. Heijmans , S. Singh , A. Lieverse , O. Gornik
Atherosclerosis 287
2019
Lp(A) Plasma Levels Are Not Associated With Microvascular Complications In T2d A Prospective Cohort Study
S. Singh , M. Licona , A. Lieverse , M. Mulder
Atherosclerosis 287
2019
In Depth Charachterization Of Dyslipidemia Beyond Conventional Lipid Panel In Patients With Type 2 Diabetes
M. Rashid , A. Verhoeven , H. van der Wiel , L. Louter
Atherosclerosis 287
2019
PCV13 Health Economic Evaluation of Screening and Treating Children with Familial Hypercholesterolemia EARLY in Life: Many Happy Returns on Investment?
Z. Ademi , R. Norman , J. Pang , D. Liew
Value in health regional issues 22
2020
THE ANGIOTENSINOGEN M235T POLYMORPHISM AND SYSTOLIC BLOOD PRESSURE IN A DUTCH MULTI-ETHNIC STUDY: P3.176
G. Mairuhu , N. R. Bindraban , G. A. Van Montfrans , E. Sijbrands
Journal of Hypertension 22
2004
INSULIN, FATTY ACID SYNTHASE, HOMOCYSTEINE LEVELS AND MEASURE OF ARTERIAL PROPERTIES. THE ROTTERDAM STUDY: 8B.05
G. Verwoert , F. Mattace-Raso , A Hofman , B Westerhof
Journal of Hypertension 29
2011
Lomitapide treatment highly affects lipoprotein profile and HDL functionality in patients with familial hypercholesterolemia
F. Zimetti , E. Favari , M.P. Adorni , N. Ronda
Atherosclerosis 241 ( 1)
2015
Effect of statins on HDL in familial hypercholesterolemia patients
M. Licona-Rashid , R. Yahya , D. Wattimena , J. Roeters van Lennep
Atherosclerosis 252
1
2016
Resistin and all-cause and cardiovascular mortality: effect modification by adiponectin in end-stage kidney disease patients
B. Spoto , F. Mattace-Raso , E. Sijbrands , P. Pizzini
Nephrology Dialysis Transplantation 28
25
2013
Mutations in the LDL receptor gene causing mRNA deficienty in heterozygous familial hypercholesterolemia
P. Lombardi , E. Sijbrands , J. Defesche , J. Kastelein
Atherosclerosis 115
1995
Effect of insulin resistance, apoE2 allele, and smoking on combined hyperlipidemia.
M JHoffer , E JSijbrands , A EMeinders , MFrölich
Arteriosclerosis and Thrombosis: A Journal of Vascular Biology
1994
Risk of type 2 diabetes attributable to C-reactive protein and other risk factors.
A. Dehghan , M. van Hoek , E. J.G. Sijbrands , T. Stijnen
Diabetes Care 30 ( 10) 2695 -2699
64
2007